



Q218 RESULTS

+2%

NET REVENUE*

\$4.1 BN

GAAP NET REVENUE
\$4.1BN

+10%

**PERFORMANCE
NET INCOME
PER SHARE***

\$4.42

GAAP LOSS PER SHARE
\$1.39

**ALLERGAN RAISED
FULL-YEAR 2018 GUIDANCE
FOR NON-GAAP NET
REVENUE & NON-GAAP
PERFORMANCE NET
INCOME PER SHARE**

**POSITIVE RESULTS
IN 7 TOPLINE STUDIES
FROM 5 KEY PIPELINE
PROGRAMS IN 1H2018**

ALLERGAN'S BOARD
OF DIRECTORS AUTHORIZES
**NEW \$2.0 BILLION SHARE
REPURCHASE PROGRAM**

*Growth percentages are versus Q2 2017.
Please refer to the GAAP to non-GAAP tables in July 26, 2018 Press Release on Allergan.com for a reconciliation of our non-GAAP results.